Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598091 · ClinicalTrials.gov registry record · Phase 1
A Phase I/Expansion Study of Dasatinib
A Phase 1 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
NCT00598091 is a Phase 1 study that was terminated before completion, run by Duke University. The registered enrollment target is 30 participants.
The verdict
NCT00598091, a Phase 1 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to find the highest dose of the drugs gemcitabine and dasatinib that can be given for the treatment of pancreatic cancer. Gemcitabine (also called Gemzar™)is a drug that is given intravenously. Dasatinib (also called Sprycel™) is a tablet and will be taken by mouth. Gemcitabine is approved by the Food and Drug Administration (FDA) for the treatment of advanced breast, lung and pancreatic cancer. Dasatinib is approved by the FDA for the treatment of chronic myeloid leukemia (CML), acute lymphoblastic leukemia or for patients that are resistant to imatinib mesylate (Gleevec™ ). This study will try to find the highest doses of these drugs that can be tolerated when taken in combination. The study will also look at how the drugs work in the body, and will see if there is any effect on pancreatic cancer.
Interventions
- DRUG dasatinib
- DRUG gemcitabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2007-04 |
| Est. Completion | 2012-05 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00598091
The ClinicalTrials.gov registry entry for NCT00598091 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which dasatinib is the first listed.
NCT00598091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00598091 about?
NCT00598091 is a clinical study titled "A Phase I/Expansion Study of Dasatinib". The purpose of this study is to find the highest dose of the drugs gemcitabine and dasatinib that can be given for the treatment of pancreatic cancer. Gemcitabine (also called Gemzar™)is a drug that is given intravenously. Dasatinib (also called Sprycel™) is a tablet and will be taken by mouth. Gem...
What is the current status of trial NCT00598091?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2007-04. Estimated completion is 2012-05.
What interventions are being tested in trial NCT00598091?
The interventions under investigation include: dasatinib (DRUG), gemcitabine (DRUG).
Who is sponsoring clinical trial NCT00598091?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.